Home
About
Overview
Sharing Data
ORCID
Help
History (7)
Polygenic Risk Scores to Identify CVD Risk and Tailor Therapy: Hope or Hype?
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial.
Uterine Fibroids: Burden and Unmet Medical Need.
Kounis Syndrome
WW Domain-Containing Oxidoreductase
See All 7 Pages
Find People
Find Everything
Edit My Profile
My Person List (
0
)
Return to Top
Login
Username
Password